中国P站

Endometrial Cancer; Cancer Stem Cells; CSC Markers; Therapeutic Targets; Drug Resistance; Tumor Microenvironment; SOX2; OCT4; Wnt Signaling; Heterogeneity

Introduction

Cancer stem cells (CSCs) are recognized as a critical driver of endometrial cancer (EC) development, progression, metastasis, and recurrence, making them a compelling target for therapeutic intervention to improve patient outcomes. Understanding the biology of these cells is paramount for developing effective treatment strategies. This review aims to consolidate current knowledge on CSC markers, their functional roles in EC, and promising therapeutic approaches designed to eliminate this highly resilient cell population [1].

Significant progress has been made in identifying specific molecular markers that characterize cancer stem cells within endometrial tumors. One such key marker is SOX2, whose expression has been directly linked to various clinicopathological features and the overall prognosis of patients with endometrial cancer. Research indicates that SOX2 may be instrumental in promoting the aggressive behavior of endometrial cancer stem cells (ECSCs), thus warranting its further investigation as a potential therapeutic target [2].

The inherent heterogeneity of endometrial cancer stem cells (CSCs) presents a substantial challenge to achieving effective treatment outcomes. This heterogeneity arises from distinct CSC subpopulations, each possessing unique properties that contribute to treatment resistance and the eventual relapse of the disease. Therefore, devising therapeutic strategies that effectively address this cellular diversity is crucial for improving patient prognoses [3].

The intricate signaling pathways that govern the self-renewal and maintenance of cancer stem cell populations are also a focal point of research. The Wnt/β-catenin signaling pathway, for instance, has been identified as playing a pivotal role in preserving the stemness of endometrial cancer stem cells (CSCs). Consequently, interventions targeting this pathway hold promise for inhibiting CSC proliferation and promoting their differentiation, potentially leading to enhanced therapeutic responses [4].

Beyond intrinsic cellular mechanisms, the tumor microenvironment (TME) exerts a profound influence on the behavior and characteristics of cancer stem cells (CSCs) in endometrial cancer. Various components within the TME, including immune cells and the extracellular matrix, can actively promote CSC survival, self-renewal capabilities, and resistance to conventional therapies. This underscores the importance of integrating TME-focused considerations into the development of treatment strategies [5].

Drug resistance is a formidable obstacle in the management of endometrial cancer, with cancer stem cells (CSCs) playing a significant role in this phenomenon. CSCs possess multiple mechanisms to evade the effects of chemotherapy and radiotherapy, such as enhanced DNA repair capabilities, increased expression of efflux pumps, and metabolic plasticity. Understanding these resistance mechanisms is essential for devising strategies to overcome them [6].

Emerging regulatory molecules, such as microRNAs (miRNAs), are increasingly recognized for their critical roles in modulating the properties of cancer stem cells (CSCs) in endometrial cancer. Specific miRNAs have been shown to influence CSC self-renewal, differentiation potential, and chemoresistance, positioning them as potential candidates for both diagnostic biomarkers and therapeutic targets in the future [7].

Another cellular characteristic associated with stemness in endometrial cancer is aldehyde dehydrogenase (ALDH) activity. Targeting ALDH activity represents a promising strategy for the elimination of cancer stem cells (CSCs) in endometrial cancer. As a known marker of CSCs, inhibiting ALDH function may significantly impair CSC capabilities and thereby reduce the likelihood of tumor recurrence [8].

Transcription factors are fundamental to maintaining cellular identity and function, and in the context of cancer stem cells, they play a crucial role in preserving stemness. OCT4, a key transcription factor, has been shown to be essential for maintaining the stemness of endometrial cancer cells. Its expression levels are often correlated with aggressive tumor characteristics, suggesting that OCT4 inhibition could be a viable therapeutic strategy [9].

Finally, the integration of immunotherapy into the treatment landscape of endometrial cancer is an active area of research, with cancer stem cells (CSCs) posing a unique challenge by evading immune surveillance. Strategies aimed at overcoming CSC-mediated immune evasion are critical for enhancing the overall efficacy of immunotherapeutic approaches in managing endometrial cancer [10].

Description

Cancer stem cells (CSCs) are recognized as key contributors to the initiation, progression, metastasis, and recurrence of endometrial cancer (EC), presenting a critical therapeutic target for improving patient outcomes. Understanding the multifaceted roles of CSCs is essential for developing effective treatment modalities. This document outlines the current understanding of CSC markers, their functional significance within the context of EC, and emerging therapeutic avenues aimed at eradicating this resilient cell population [1].

Research has identified specific markers associated with endometrial cancer stem cells (ECSCs), with SOX2 emerging as a particularly significant one. Its expression levels have been correlated with distinct clinicopathological features and can serve as a prognostic indicator for patients. The study suggests that SOX2 may actively promote the aggressive characteristics of ECSCs, highlighting its potential as a target for novel therapeutic interventions [2].

A significant hurdle in the effective treatment of endometrial cancer is the inherent heterogeneity observed among cancer stem cell (CSC) populations. This heterogeneity manifests as distinct CSC subpopulations with varying biological properties, which can contribute to resistance against therapies and lead to disease relapse. Consequently, therapeutic strategies must be designed to address and overcome this cellular diversity [3].

The Wnt/β-catenin signaling pathway has been implicated in the fundamental processes of maintaining stemness in cancer cells. In endometrial cancer stem cells (CSCs), this pathway plays a crucial role in regulating their self-renewal and survival. Targeting the Wnt/β-catenin pathway is being explored as a potential strategy to inhibit CSC proliferation and induce differentiation, thereby enhancing treatment efficacy [4].

The tumor microenvironment (TME) is increasingly acknowledged as a critical factor influencing the behavior and survival of cancer stem cells (CSCs) in endometrial cancer. Components of the TME, such as the immune cell infiltrate and the extracellular matrix, can create a supportive niche that promotes CSC self-renewal and confers resistance to various therapeutic agents. This emphasizes the need to consider the TME when devising treatment plans [5].

Drug resistance remains a significant challenge in the management of endometrial cancer, and cancer stem cells (CSCs) are major contributors to this phenomenon. CSCs employ various sophisticated mechanisms to evade the cytotoxic effects of chemotherapy and radiotherapy, including enhanced DNA repair pathways, increased drug efflux pump activity, and metabolic adaptability. Addressing these resistance mechanisms is crucial for overcoming treatment failures [6].

MicroRNAs (miRNAs), small non-coding RNA molecules, are emerging as important regulators of cancer stem cell (CSC) phenotypes in endometrial cancer. Specific miRNAs have demonstrated the ability to influence CSC self-renewal, differentiation, and resistance to chemotherapy. This has led to their consideration as potential diagnostic biomarkers and therapeutic targets for endometrial cancer [7].

Aldehyde dehydrogenase (ALDH) activity is a well-established hallmark of cancer stem cells (CSCs) across various cancers, including endometrial cancer. Targeting ALDH activity presents a viable strategy for the selective elimination of CSCs. By inhibiting ALDH function, it is anticipated that CSC proliferation and their contribution to tumor recurrence can be significantly curtailed [8].

Transcription factors are fundamental regulators of cellular identity and are vital for maintaining stemness. OCT4, a well-known pluripotency transcription factor, has been identified as essential for preserving the stemness of endometrial cancer cells. Its expression is frequently associated with more aggressive tumor characteristics, suggesting that OCT4 could be a valuable therapeutic target for combating endometrial cancer [9].

Immunotherapy has shown promise in the treatment of various cancers, and its application in endometrial cancer is under active investigation. However, cancer stem cells (CSCs) possess the ability to evade immune surveillance, thereby limiting the effectiveness of immunotherapeutic strategies. Research is focusing on methods to overcome CSC-mediated immune evasion to enhance treatment outcomes [10].

Conclusion

Cancer stem cells (CSCs) are crucial drivers of endometrial cancer (EC) development, metastasis, and recurrence, making them a key therapeutic target. Studies have identified markers like SOX2 and OCT4 associated with CSCs and their aggressive behavior. CSC heterogeneity poses a therapeutic challenge, while signaling pathways such as Wnt/β-catenin and factors like aldehyde dehydrogenase activity and microRNAs regulate CSC properties. The tumor microenvironment significantly influences CSCs, and CSCs contribute to drug resistance through mechanisms like enhanced DNA repair. Targeting CSCs and overcoming their immune evasion are critical for improving EC treatment outcomes.

References

1. Laura AE, Mohamed YE, Sandro GDS. (2021) .Cancers 13:13(18):4592.

   , ,

2. Li W, Shijie Z, Li Y. (2022) .Front Oncol 12:12:834198.

   , ,

3. Elina KG, Panagiotis M, Dimitrios EK. (2021) .Int J Mol Sci 22:22(17):9203.

   , ,

4. Ying Z, Kaijun C, Chunyi B. (2023) .Cells 12:12(2):327.

   , ,

5. Chiara D, Silvia M, Massimo PF. (2023) .J Clin Med 12:12(17):5614.

   , ,

6. Annalisa GZ, Andrea MDS, Anna MM. (2022) .Biomedicines 10:10(10):2354.

   , ,

7. Jing L, Yanxia Z, Wenjing L. (2023) .Front Oncol 13:13:1110984.

   , ,

8. Hongfei L, Huimei L, Zhengwei L. (2021) .Mol Ther Oncolytics 20:20:334-342.

   , ,

9. Ying L, Yiran W, Chao Y. (2023) .J Gynecol Oncol 34:34(1):e10.

   , ,

10. Xin X, Qing Z, Xiaoli G. (2022) .Front Immunol 13:13:947562.

    , ,